ReviewFrontiers in immunology2026
SLC25 in intestinal inflammation: mechanisms, pathological roles, and therapeutic implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) represent a spectrum of chronic gastrointestinal disorders fueled by a complex multifactorial interplay, where mitochondrial dysfunction has emerged as a critical contributor. The SLC25 family of mitochondrial transporters mediates the exchange of essential metabolites across the mitochondrial inner membrane, serving as pivotal regulators of cellular energy homeostasis in both the intestinal epithelium and immune cells. Accumulating evidence indicates that dysregulation of SLC25-dependent metabolic transport disrupts the crosstalk between cellular metabolism and immune signaling, driving chronic intestinal inflammation. This review comprehensively examines the pathological roles of SLC25 proteins across three interconnected dimensions: epithelial barrier disruption, immune dysregulation, and host-microbiota metabolic crosstalk. Specifically, we synthesize current findings on how altered SLC25 function compromises the intestinal barrier via oxidative stress and energy deficits, skews immune cell polarization toward pro-inflammatory states, and perpetuates a vicious cycle of microbial dysbiosis. Ultimately, this review provides a comprehensive theoretical basis for the central role of SLC25-mediated metabolic reprogramming in IBD pathogenesis, and establishes a critical mechanistic foundation for the development of novel metabolism-targeted therapeutics and diagnostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.